Resume af teksten:
Præsident Trump har indført en 15% told på EU-farmaceutiske produkter og truer med højere afgifter andre steder, mens han samtidig kræver, at amerikanske medicinalfirmaer sænker priserne. USA og EU har efter forhandlinger indgået en handelsaftale, hvor en 15% told på de fleste EU-eksporterede varer erstatter den tidligere truede 30%. For Schweiz pålægges en 39% told, med undtagelse af farmaceutiske produkter for nuværende. Indien risikerer en 25% told, hvilket kan påvirke deres eksport af generiske lægemidler. ING’s Diederik Stadig diskuterer, hvordan disse tiltag kan påvirke medicinalindustrien, forbrugerne og Trumps overordnede strategi.
Fra ING:
President Trump has imposed a 15% tariff on EU pharmaceuticals and threatened even steeper levies elsewhere. At the same time, however, he is demanding that drug companies at home lower their prices. In this podcast, ING’s Diederik Stadig explains why these competing aims cannot be reconciled, and what it could all mean for the industry and for consumers
Following months of high-stakes negotiations, a US-EU trade deal has now been clinched, with a 15% tariff on most EU exports replacing the feared 30% threatened by Trump earlier this year. The White House has since confirmed that pharmaceuticals will fall under this 15% threshold.
While the decision offers some clarity to EU companies, uncertainty looms elsewhere. Switzerland faces a steep 39% tariff on exports, though pharmaceuticals appear exempt for now. Meanwhile, India – a major supplier of generic drugs – could be hit with a 25% tariff.
In this podcast, ING’s Diederik Stadig joins Rebecca Byrne and Olivia Grace to discuss the implications for the pharma industry, for consumers, and for Trump’s strategy itself.
Hurtige nyheder er stadig i beta-fasen, og fejl kan derfor forekomme.
